Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3181-3195

  Driver, Emily R ^a   Ryan, Gavin J ^a   Hoff, Donald R ^a   Irwin, Scott M ^a   Basaraba, Randall J ^a   Kramnik, Igor ^b   Lenaerts, Anne J ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; LINEZOLID; METRONIDAZOLE; PIMONIDAZOLE; PYRAZINAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; BAGG ALBINO MOUSE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; EXPERIMENTAL MOUSE; EXTRACELLULAR SPACE; FEMALE; HYPOXIA; INTRACELLULAR SPACE; KRAMNIK MOUSE; LUNG FIBROSIS; MOUSE; NECROSIS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; GRANULOMA; METRONIDAZOLE; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE;

EID: 84861163743     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00217-12     Document Type: Article

References (68)

1. AFIP. 1968. Manual of histological staining methods of the Armed Forces Institute of Pathology, 3rd ed. McGraw Hill Publications, New York, NY.
2. Ahmad Z, et al. 2011. Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis. Antimicrob. Agents Chemother. 55:1527-1532.
3. Ahmad Z, et al. 2009. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J. Infect. Dis. 200:1136-1143.
4. Ahmad Z, et al. 2010. Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. J. Antimicrob. Chemother. 65:729-734.
5. Aly S, et al. 2006. Oxygen status of lung granulomas in Mycobacterium tuberculosis-infected mice. J. Pathol. 210:298-305. (Pubitemid 44660508)
6. Barry CE, Boshoff HI, Dowd CS. 2004. Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr. Pharm. Des. 10:3239-3262. (Pubitemid 39276613)
7. Basaraba RJ. 2008. Experimental tuberculosis: the role of comparative pathology in the discovery of improved tuberculosis treatment strategies. Tuberculosis (Edinb.) 88(Suppl 1):S35-S47.
8. Brooks JV, Furney SK, Orme IM. 1999. Metronidazole therapy in mice infected with tuberculosis. Antimicrob. Agents Chemother. 43:1285-1288. (Pubitemid 29214765)
9. Burman W, et al. 2006. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am. J. Respir. Crit. Care Med. 173:350-356. (Pubitemid 43209091)
10. Canetti G. 1955. The tubercle bacillus in the pulmonary lesion of man: histobacteriology and its bearing on the therapy of pulmonary tuberculosis. Springer Publication Co., New York, NY.
11. Crowle AJ, Sbarbaro JA, May MH. 1986. Inhibition by pyrazinamide of tubercle bacilli within cultured human macrophages. Am. Rev. Respir. Dis. 134:1052-1055. (Pubitemid 17171671)
12. Davies GR, Pym AS, Mitchison DA, Nuermberger EL, Grosset JH. 2007. Evaluation of new antituberculosis drugs in mouse models. Antimicrob. Agents Chemother. 51:403-404. (Letter.)
13. 18F]-2-fluoro- deoxy-Dglucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob. Agents Chemother. 53:4879-4884.
14. Dayan D, Hiss Y, Hirshberg A, Bubis JJ, Wolman M. 1989. Are the polarization colors of picrosirius red-stained collagen determined only by the diameter of the fibers? Histochemistry 93:27-29. (Pubitemid 19272698)
15. De Groote MA, et al. 2011. Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 55:1237-1247.
16. Dhillon J, Allen BW, Hu Y-M, Coates ARM, Mitchison DA. 1998. Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int. J. Tuberc. Lung Dis. 2:736-742. (Pubitemid 28429724)
17. Early MA, et al. 2009. Non-invasive diagnosis of early pulmonary disease in PECAM-deficient mice using infrared pulse oximetry. Exp. Mol. Pathol. 87:152-158.
18. Ehlers S. 2009. Lazy, dynamic or minimally recrudescent? On the elusive nature and location of the mycobacterium responsible for latent tuberculosis. Infection 37:87-95.
19. Flynn JL, et al. 2003. Non-human primates: a model for tuberculosis research. Tuberculosis (Edinb.) 83:116-118. (Pubitemid 36683560)
20. Ford CB, et al. 2011. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nature Genetics 43:482-486.
21. Heifets L, Lindholm-Levy P. 1992. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am. Rev. Respir. Dis. 145:1223-1225.
22. Hoff DR, et al. 2008. Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 52:4137-4140.
23. Hoff DR, et al. 2011. Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment. PLoS One 6:e17550.
24. Hunter RL, Jagannath C, Actor JK. 2007. Pathology of postprimary tuberculosis in humans and mice: contradiction of long-held beliefs. Tuberculosis (Edinb.) 87:267-278. (Pubitemid 46951032)
25. Jain SK, et al. 2007. Accelerated detection of Mycobacterium tuberculosis genes essential for bacterial survival in guinea pigs, compared with mice. J. Infect. Dis. 195:1634-1642. (Pubitemid 46799221)
26. Kaplan G, et al. 2003. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect. Immun. 71:7099-7108. (Pubitemid 37475342)
27. Keller C, Lauber J, Blumenthal A, Buer J, Ehlers S. 2004. Resistance and susceptibility to tuberculosis analysed at the transcriptome level: lessons from mouse macrophages. Tuberculosis (Edinb.) 84:144-158. (Pubitemid 38857848)
28. Kim MJ, et al. 2010. Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol. Med. 2:258-274.
29. Kjellsson MC, et al. 2012. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob. Agents Chemother. 56:446-457.
30. Kramnik I. 2008. Genetic dissection of host resistance to Mycobacterium tuberculosis: the sst1 locus and the Ipr1 gene. Curr. Top. Microbiol. Immunol. 321:123-148.
31. Kramnik I, Demant P, Bloom BB. 1998. Susceptibility to tuberculosis as a complex genetic trait: analysis using recombinant congenic strains of mice. Novartis Found. Symp. 217:120-132.
32. Kramnik I, Dietrich WF, Demant P, Bloom BR. 2000. Genetic control of resistance to experimental infection with virulent Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 97:8560-8565. (Pubitemid 30639712)
33. Lenaerts AJ, Gruppo V, Brooks JV, Orme IM. 2003. Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. Antimicrob. Agents Chemother. 47:783-785. (Pubitemid 36158115)
34. Lenaerts AJ, et al. 2005. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother. 49:2294-2301. (Pubitemid 40734457)
35. Li M, et al. 2011. Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension. J. Immunol. 187:2711-2722.
36. Lin PL, et al. 2006. Early events in Mycobacterium tuberculosis infection in cynomolgus macaques. Infect. Immun. 74:3790-3803. (Pubitemid 43993310)
37. Manabe YC, et al. 2008. The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. Tuberculosis (Edinb.) 88:187-196.
38. Miner MD, Chang JC, Pandey AK, Sassetti CM, Sherman DR. 2009. Role of cholesterol in Mycobacterium tuberculosis infection. Indian J. Exp. Biol. 47:407-411.
39. Munoz-Elias EJ, et al. 2005. Replication dynamics of Mycobacterium tuberculosis in chronically infected mice. Infect. Immun. 73:546-551. (Pubitemid 40041149)
40. Nedeltchev GG, et al. 2009. Extrapulmonary dissemination of Mycobacterium bovis but not Mycobacterium tuberculosis in a bronchoscopic rabbit model of cavitary tuberculosis. Infect. Immun. 77:598-603.
41. Nuermberger E, et al. 2006. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother. 50:2621-2625. (Pubitemid 44198679)
42. Nuermberger EL, et al. 2004. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am. J. Respir. Crit. Care Med. 170:1131-1134. (Pubitemid 39488628)
43. Ordway DJ, et al. 2010. Evaluation of standard chemotherapy in the guinea pig model of tuberculosis. Antimicrob. Agents Chemother. 54:1820-1833.
44. Orme IM. 1996. Immune responses in animal models. Curr. Top. Microbiol. Immunol. 215:181-196. (Pubitemid 26270596)
45. Orme IM. 2003. The mouse as a useful model of tuberculosis. Tuberculosis 83:112-115. (Pubitemid 36683559)
46. Palanisamy GS, et al. 2009. Clinical strains of Mycobacterium tuberculosis display a wide range of virulence in guinea pigs. Tuberculosis (Edinb.) 89:203-209.
47. Pan H, et al. 2005. Ipr1 gene mediates innate immunity to tuberculosis. Nature 434:767-772. (Pubitemid 44739520)
48. Pichugin AV, Yan BS, Sloutsky A, Kobzik L, Kramnik I. 2009. Dominant role of the sst1 locus in pathogenesis of necrotizing lung granulomas during chronic tuberculosis infection and reactivation in genetically resistant hosts. Am. J. Pathol. 174:2190-2201.
49. Prideaux B, et al. 2011. High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal. Chem. 83:2112-2118.
50. Rosenthal IM, et al. 2006. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am. J. Respir. Crit. Care Med. 174:94-101. (Pubitemid 43955249)
51. Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F. 2009. Foamy macrophages and the progression of the human tuberculosis granuloma. Nat. Immunol. 10:943-948.
52. Rustad TR, Sherrid AM, Minch KJ, Sherman DR. 2009. Hypoxia: a window into Mycobacterium tuberculosis latency. Cell. Microbiol. 11:1151-1159.
53. Ryan GJ, et al. 2010. Multiple M. tuberculosis phenotypes in mouse and guinea pig lung tissue revealed by a dual-staining approach. PLoS One 5:e11108.
54. Schnoor M, et al. 2008. Production of type VI collagen by human macrophages: a new dimension in macrophage functional heterogeneity. J. Immunol. 180:5707-5719.
55. Shang S, et al. 2011. Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in Guinea pigs. Antimicrob. Agents Chemother. 55:124-131.
56. Singh P, et al. 2007. Comparative evaluation of Lowenstein-Jensen proportion method, BacT/ALERT 3D system, and enzymatic pyrazinamidase assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 45:76-80. (Pubitemid 46106409)
57. Sissons J, et al. 2009. Multigenic control of tuberculosis resistance: analysis of a QTL on mouse chromosome 7 and its synergism with sst1. Genes Immun. 10:37-46.
58. Solotorovsky M, et al. 1952. Pyrazinoic acid amide; an agent active against experimental murine tuberculosis. Proc. Soc. Exp. Biol. Med. 79:563-565.
59. Somoskovi A, et al. 2001. Lessons from a proficiency testing event for acid-fast microscopy. Chest 120:250-257. (Pubitemid 32744887)
60. Tsai MC, et al. 2006. Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension. Cell. Microbiol. 8:218-232. (Pubitemid 43356045)
61. Vernon A, Burman W, Benator D, Khan A, Bozeman L. 1999. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 353:1843-1847. (Pubitemid 29251017)
62. Via LE, et al. 2008. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect. Immun. 76:2333-2340.
63. Wade MM, Zhang Y. 2004. Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis. J. Med. Microbiol. 53:769-773. (Pubitemid 39430363)
64. Wayne LG, Hayes LG. 1996. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64:2062-2069. (Pubitemid 26165667)
65. WHO. 2009. Global tuberculosis control: a short update to the 2009 report. WHO Press, World Health Organization, Geneva, Switzerland.
66. Yan BS, et al. 2007. Progression of pulmonary tuberculosis and efficiency of bacillus Calmette-Guerin vaccination are genetically controlled via a common sst1-mediated mechanism of innate immunity. J. Immunol. 179:6919-6932.
67. Zhang M, et al. 2011. Treatments of tuberculosis with rifamycincontaining regimens in immune-deficient mice. Am. J. Respir. Crit. Care Med. 183:1254-1261.
68. Zhang Y, Mitchison D. 2003. The curious characteristics of pyrazinamide: a review. Int. J. Tuberc. Lung Dis. 7:6-21. (Pubitemid 36427026)